Lumidol

Quick links to important sections

Lumidol

Treatment option: Pain, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lumidol

Quick Facts: Lumidol Identity

Property Description
Active ingredient Tramadol Hydrochloride
Form Oral forms (tablets, capsules, solution), Injectable solution
Pharmacological class Opioid Analgesic
General purpose Pain Management
Origin Synthetic substance

What Type of Medicine is Lumidol?

Lumidol is a pharmaceutical preparation that acts as a centrally acting opioid analgesic, primarily intended for effective pain management. The active ingredient is the synthetic substance Tramadol Hydrochloride, which is manufactured through chemical synthesis rather than being derived directly from a natural source. The drug is classified as an opioid agonist by regulatory bodies. This medication works by altering the central nervous system's perception of pain. As a monosegmental drug, Lumidol is characterized by containing only the single active compound Tramadol Hydrochloride, distinguishing it from combination analgesics.

Composition and Available Pharmaceutical Forms

The core composition of Lumidol relies on the active ingredient Tramadol Hydrochloride, combined with standard, inactive pharmaceutical excipients used as the base/vehicle to facilitate its stability and proper delivery. Lumidol is produced in multiple dosage forms to accommodate various requirements and methods of administration. These forms include solid oral forms, such as tablets and capsules, an oral solution, and injectable solutions for parenteral administration. Its availability in diverse forms, particularly the quick-acting oral and injectable formats, supports varied pain relief strategies.

How Lumidol Works for General Pain Management

The general purpose of Lumidol is to provide pain relief by directly influencing how the central nervous system processes and transmits pain signals. This is achieved through the drug’s characteristic dual action: weak binding to mu-opioid receptors and the simultaneous modulation of the neurotransmitters norepinephrine and serotonin. This combined approach ensures the medicine addresses the neurological component of pain, making it suitable for situations requiring comprehensive relief. This means the medication is fundamentally designed to diminish the sensation of pain by boosting the body's natural pain-inhibiting systems.

Regulatory References

  1. Tramadol hydrochloride: Mechanism of Action
  2. Tramadol Hydrochloride: Opioid Agonist
  3. Tramadol Hydrochloride: Active Ingredient
  4. Tramadol Hydrochloride: Dosage Forms
  5. Tramadol: Action on CNS
  6. Binding to Mu-opioid Receptors
  7. Modulation of Norepinephrine
  8. Modulation of Serotonin

What side effects are possible with Lumidol?

Possible side effects and safety information

The safety profile of Lumidol (Tramadol Hydrochloride) is defined by official regulatory documentation, which classifies adverse reactions by frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their rate of occurrence as observed in regulatory studies. Very Common (ge 10%) reactions include Nausea and Dizziness. Common (ge 1% to < 10%) reactions typically involve the gastrointestinal system and include Vomiting, Constipation, Dry mouth, and central nervous system effects such as Somnolence, Headache, and Sweating.

Systemic Safety and Serious Risks

Adverse reactions are formally grouped by System-Organ Class (SOC), including disorders of the Nervous system, Gastrointestinal tract, and Psychiatric disorders. The official safety information highlights specific Serious Adverse Reactions, which, though Rare (< 0.1%), are clinically significant.

These serious risks include Respiratory Depression, which is potentially life-threatening and of highest risk upon treatment initiation or following a dosage increase. Other rare but serious events documented in regulatory labels are Seizures/Convulsions, Serotonin Syndrome (especially when used with other serotonergic agents), and Anaphylactic Reactions. Long-term use is associated with the risk of developing physical dependence and withdrawal symptoms.

Population-Specific Safety Considerations

The regulatory label includes specific constraints for defined patient groups. Use is not recommended in children younger than 12 years of age, and specific cautions apply to adolescents (12–18 years) with certain risk factors. Furthermore, greater caution is advised for Older Adults (over 75 years) and patients with severe renal or hepatic impairment, as clearance of the medicine may be affected, potentially increasing the risk of adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based on official government regulatory documents detailing the potential outcomes of Lumidol overexposure.

Overdose presents a serious, life-threatening risk, primarily due to the potential for severe respiratory depression. Accidental ingestion, particularly by children, may result in a fatal outcome. Overdose manifestations are often severe and require immediate medical intervention.


Documented Overdose Manifestations

Symptoms documented in regulatory labeling may include:

  • Central Nervous System (CNS) Depression: Profound sedation, extreme somnolence, stupor, or coma.
  • Respiratory Compromise: Slowed, shallow breathing, long pauses between breaths, or complete cessation of breathing (fatal risk).
  • Cardiovascular Signs: Severe hypotension (low blood pressure) and a slowed heart rate.
  • Physical Signs: Miosis (pinpoint pupils) and cold, clammy skin.

Required Emergency Actions

The official labeling provides strict guidance on when to seek urgent medical attention:

Condition Immediate Action
Signs of Respiratory Failure Call 911 or emergency medical services immediately.
Unresponsiveness or Inability to Wake Up Contact a Poison Control Center or Emergency Medical Services.

Immediate medical help is required if the patient exhibits any sign of severe respiratory distress or profound alteration in consciousness. The management of overdose, including the use of an opioid reversal agent (if applicable and specified in the label), and supportive measures must be initiated by medical professionals in a monitored setting. Patients with pre-existing conditions or those taking other CNS depressants may face increased risk.

Therapeutic Uses of Lumidol

What Lumidol Treats: Main Uses and Benefits

Lumidol (Tramadol Hydrochloride) is used for the management of pain. It is indicated to treat moderate to moderately severe pain in adults. It is relevant when supportive symptom management is appropriate due to symptoms being difficult to tolerate and create noticeable physiological strain.

Therapeutic Scope and Benefits

Lumidol is commonly used to help manage symptoms related to physical discomfort that interfere with daily functioning. This support helps ease the overall symptom load, which may assist with maintaining functional stability.

It is relevant for conditions characterized by periods of heightened symptoms, such as the acute pain often experienced after an operation or injury, and may be part of symptomatic management for persistent, long-term pain. It assists with managing symptoms that may become intense or disruptive and offers symptomatic relief that helps patients cope more steadily.


Quick Fact: Symptomatic Relief Domains
Symptom Focus: Symptoms that create noticeable physiological strain
Use Contexts: Acute episodes and sustained chronic management
Key Benefit: Provides supportive relief when symptoms interfere with routine activities

Eligibility and Restrictions for Use

Who can and cannot use Lumidol?

Lumidol’s eligibility profile is strictly defined by regulatory authorities based on age, underlying physiological status, and concurrent treatment. The medicine is approved for use in the adult population (18 years and older) under standard labeled conditions.


Populations with Restrictions or Contraindications

Lumidol is contraindicated (must not be used) for several groups as specified in official labeling. Use is not recommended or restricted for other populations:

Eligibility Status Population/Condition
Contraindicated Children younger than 12 years of age. Patients with severe respiratory depression or acute bronchial asthma. Patients with gastrointestinal obstruction. Patients currently using Monoamine Oxidase Inhibitors (MAOIs).
Not Recommended Women during pregnancy (risk of Neonatal Opioid Withdrawal Syndrome) or breastfeeding. Patients with severe renal or hepatic impairment.

Use is also contraindicated in adolescents under 18 following tonsillectomy or adenoidectomy. For adolescents (12–17) with specific risk factors (e.g., obesity, sleep apnea) and older adults (over 75), use is restricted and requires specific caution. Individuals identified as ultra-rapid metabolizers should not use this medication due to regulatory warnings.

What should I know about interactions with other medicines?

The officially documented interaction profile for Lumidol (Tramadol Hydrochloride) is structured around prohibited combinations and clinically significant co-administration risks.

Formal Regulatory Contraindications

Lumidol is formally contraindicated for use in patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing such treatment. Additionally, the medicine is contraindicated in children younger than 12 years of age and in adolescents younger than 18 years following tonsillectomy or adenoidectomy.

Pharmacodynamic Interactions

Co-administration with other Central Nervous System (CNS) depressants, including benzodiazepines and other opioid products, carries the regulatory warning of profound sedation, respiratory depression, and potentially death due to additive effects. Furthermore, combining Lumidol with serotonergic agents, such as SSRIs and SNRIs, may lead to the life-threatening condition known as Serotonin Syndrome. There is also a documented increased risk of seizures when Lumidol is used with other medications that lower the seizure threshold.

Metabolic and Exposure Alterations

The drug’s metabolism via Cytochrome P450 (CYP) enzymes results in specific pharmacokinetic interactions. Co-administration with inhibitors of CYP2D6 and CYP3A4 may increase the plasma concentrations of Lumidol. Conversely, inducers of these enzymes, such as Carbamazepine, may increase metabolism, which can formally reduce the analgesic effect. Consumption of alcohol-containing beverages is also restricted due to the potentiation of the CNS depressant effects.

Mechanism of Action

Lumidol is a small molecule antagonist that acts on two distinct biochemical targets to modulate bone turnover. The compound binds competitively to Receptor A on the surface of osteoclast progenitor cells, thereby inhibiting the downstream activation of the NF-kappaB signaling pathway. This antagonism reduces the differentiation and maturation of osteoclasts.

Concurrently, Lumidol inhibits the activity of Enzyme X in osteoblasts. The resulting enzymatic modulation promotes the expression of osteoprotegerin (OPG) and decreases the expression of RANKL on the osteoblast surface. This dual action mechanism alters the expression profile of osteoblast and osteoclast differentiation markers. This coordinated effect influences the net bone remodeling rate and modifies the receptor-mediated flux of calcium ions.

Dosage and Administration Information

Lumidol administration is standardized across two principal methods: the oral route, which includes immediate-release (IR) and extended-release (ER) forms, and the parenteral route, utilizing injectable solutions for intravenous (I.V.) or intramuscular (I.M.) use. The dosing regimen is fundamentally defined by the selected formulation. Immediate-Release oral forms are typically administered every 4 to 6 hours, adhering to a strict adult maximum daily dose of 400 mg. These forms may be taken without regard to food.

For continuous management, the Extended-Release forms are used, requiring once-daily administration with a maximum daily dose restricted to 300 mg. An explicit administration constraint is that ER forms must be swallowed entirely whole; they cannot be split, chewed, or crushed, as this compromises the intended release mechanism.

The official procedural structure requires a gradual approach to dose management. Treatment initiation involves a titration schedule, where the low starting dose is gradually increased in small increments over several days. Similarly, discontinuation of the medicine mandates a gradual tapering of the dosage, rather than abrupt cessation, as part of the established protocol. Furthermore, specific population-based adjustments are required, such as extending the dosing interval to 12 hours for patients with severe renal impairment or limiting the daily dose for adults over 75.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies


Evidence for Use in Acute Pain Settings

Lumidol was studied for use in acute or disruptive episodes, such as those experienced right after an operation or injury. The primary evidence comes from short-term, controlled clinical trials, where researchers typically examined outcomes following a single dose. Studies measured outcomes related to physical discomfort, such as changes in pain scores over a few hours. Studies reported how symptoms evolved in the observed populations in the immediate hours following administration. The follow-up durations in these acute pain studies were generally limited.

Evidence for Use in Chronic Pain Management

Lumidol was studied for use in patients with conditions where symptoms may vary in intensity. The evidence base is compiled through systematic reviews and meta-analyses. Research examined outcomes reflecting daily functioning or activity level as well as pain intensity over periods of several weeks. Systematic reviews and combined data show patterns related to changes in pain scores across different chronic pain conditions. Long-term effects are not fully established regarding sustained functional preservation, as the core controlled trials are typically short, lasting only a few weeks to three months.

Evidence in Specific Chronic Conditions (e.g., Osteoarthritis)

Specific trials were evaluated in populations with painful osteoarthritis, a condition marked by functional limitations. Research examined outcomes related to functional imbalance, such as scores related to joint pain and the ability to perform daily physical activities. The documented outcomes in these studies described patterns of change when compared to a placebo. These findings contribute to the broader evidence landscape used in regulatory evaluations. Limited information is available for patients with more severe disease stages or other forms of arthritis besides knee and hip OA.

Gaps and Areas of Research Uncertainty

The evidence highlights what is known — and what is still uncertain. The short follow-up durations common in many trials mean that the long-term effects are not fully established. Comparative evidence is lacking for many head-to-head trials against newer, non-opioid medications. Limited information is available for certain groups, such as the pediatric population, and sample sizes were modest for some studies in older adults.

Frequently Asked Questions (FAQ)

Common questions about Lumidol (FAQ)


Q: How quickly do most people start feeling the effects of Lumidol?

According to official product information, the onset of pain relief for the immediate-release oral form of Lumidol generally begins within one hour of taking the medication. The peak effects of the dose are typically described as occurring within two to four hours after administration.


Q: Can Lumidol be taken with common over-the-counter pain relievers?

Official health guidance suggests that co-administration with common, non-opioid, over-the-counter pain relievers is typically acceptable. The guidance often notes paracetamol (acetaminophen) and ibuprofen as examples where co-use may be permitted.


Q: Is Lumidol the same type of medication as [similar drug name]?

Regulatory classification identifies Lumidol as a centrally acting opioid analgesic. This means the active ingredient, Tramadol hydrochloride, is a synthetic substance that works in the central nervous system to manage pain. It is officially described in documents by its pharmacological class.


Q: What happens if a person forgets to take a dose of Lumidol?

If a dose is missed, regulatory patient information instructs that the missed dose should be skipped entirely. The patient is advised to resume their regular schedule for the next planned dose and should not take a double dose to make up for the one they missed.


Q: Is it normal to feel [minor, vague symptom] when starting Lumidol?

Official safety information reports that common or very common adverse effects include nausea, dizziness, somnolence (sleepiness), and constipation. Furthermore, regulatory warnings note that the risk of serious side effects, such as respiratory depression, is described as being highest when treatment is first initiated or the dose is increased.


Q: Are there any food or drinks that should be avoided when using Lumidol?

The consumption of alcohol is restricted because it can significantly potentiate the depressant effects on the central nervous system. Extended-release forms of the medication can typically be taken without regard to food, but it is recommended to take the medication in a consistent manner (either always with or always without food).


Q: Is Lumidol meant for short-term or long-term use?

The medication is indicated for use in managing chronic pain that requires continuous treatment for an extended period. However, regulatory guidance consistently emphasizes that it should be used at the lowest effective dose for the shortest possible duration.


Q: Does Lumidol require a specific diet change?

No specific diet change is described as being required by regulatory documents beyond the mandated restriction of alcohol consumption. Both immediate-release and extended-release forms can generally be taken without regard to food.


Q: What should a patient do if they experience a severe allergic reaction to Lumidol?

The official safety information documents that serious allergic reactions, including anaphylaxis, have been reported, although they are rare. Regulatory warnings advise that emergency medical help should be sought immediately if a patient experiences any signs of a severe allergic reaction.


Q: Is Lumidol addictive or habit-forming?

Lumidol is an opioid, and regulatory information carries a Boxed Warning noting the risk of addiction, abuse, misuse, and physical dependence associated with its use, even when prescribed appropriately. This is a characteristic of this class of medication.


Q: How long does Lumidol stay in the system after the last dose?

Official pharmacokinetics data indicates that the mean elimination half-life of Lumidol is approximately 6.3 to 7 hours. It generally takes about five half-lives for the drug to be considered fully cleared from the system.


Q: Are there any known interactions between Lumidol and common herbal supplements?

Authoritative health resources list potential interactions between Lumidol and certain herbal products. These substances, such as St. John's wort and Tryptophan, have been associated with a potential risk of serious conditions like Serotonin Syndrome due to their effects on neurotransmitters.


Q: Does Lumidol affect a person's ability to drive or operate machinery?

The regulatory label contains an explicit warning that Lumidol may impair the mental and/or physical abilities necessary for performing potentially hazardous tasks. This includes activities such as driving a vehicle or operating complex machinery.


Q: What should be discussed with a healthcare provider before starting Lumidol?

Regulatory information advises patients to discuss all prescription and nonprescription medications, vitamins, and supplements with a healthcare provider. The guidance also emphasizes the disclosure of any personal or family history of substance abuse or addiction.


Q: Is there a generic version of Lumidol available?

Yes, official documents from the FDA confirm that generic versions of the active ingredient, Tramadol hydrochloride, have been approved. These generic formulations are widely available.


Q: Is it possible for Lumidol to stop working after a period of time?

Tolerance may develop with opioid use, and this can be characterized by a need for increased dosage to maintain the same effect. Regulatory guidance advises for the periodic reassessment of the continued need for the medication to address this potential change.


Q: Are there any specific organs that Lumidol is known to affect?

The official safety profile indicates that the medicine may affect several systems and organs, particularly the central nervous system (CNS), the respiratory system, the gastrointestinal system, and the endocrine system (adrenal glands). Specific cautions are advised for patients with severe kidney or liver impairment.


Q: Why is Lumidol sometimes associated with [specific minor side effect]?

Common adverse effects like dizziness, nausea, and somnolence are often associated with the drug's fundamental function. These effects are typically related to Lumidol's action on the central nervous system and its opioid agonist properties.


Q: How does the body typically process Lumidol?

The body processes Lumidol through a sequence of steps that involve absorption, distribution, metabolism, and excretion. Metabolism primarily occurs in the liver via Cytochrome P450 (CYP) enzymes, mainly CYP2D6 and CYP3A4, and the final products are mainly excreted by the kidneys.


Q: What are the criteria for stopping Lumidol, according to official sources?

Regulatory guidelines mandate that discontinuation of Lumidol involves gradually tapering the dosage over time, rather than abruptly ceasing the medication. This protocol is required to reduce the risk of withdrawal symptoms.


Q: What warnings exist for people who are planning surgery while taking Lumidol?

The medicine is strictly contraindicated for adolescents following tonsillectomy or adenoidectomy surgery. General warnings regarding profound sedation and respiratory depression are highly relevant to any surgical procedure and apply to all patients taking the medicine.


Q: What is the purpose of the different strengths Lumidol comes in?

The different strengths and formulations, such as immediate-release (IR) and extended-release (ER), are supplied to allow for individual dose titration and management of pain severity. This variety helps the prescriber minimize the total daily dose while effectively managing symptoms.


Q: Are there any known interactions between Lumidol and grapefruit juice?

Grapefruit juice may inhibit the CYP3A4 enzyme, a key component involved in processing Lumidol in the liver. Official drug interaction information notes that inhibition of this enzyme may lead to increased plasma concentrations of the drug.


How should Lumidol be stored and disposed of?

Storage and Disposal of Lumidol (Tramadol Hydrochloride)

Storage Conditions

Lumidol must be stored at Controlled Room Temperature (CRT), typically maintained between 20°C and 25°C (68°F and 77°F). The medication must be kept in its original container, which should be tightly closed, and the product must be protected from moisture to maintain stability.

Child Safety Requirements

Due to the risks associated with opioid analgesics, Lumidol must be stored securely and kept out of the sight and reach of children and pets to prevent accidental ingestion, which can result in fatal overdose.

Official Disposal Instructions

Unused or expired Lumidol must be disposed of promptly. The preferred method is using a drug take-back program. If a take-back option is not immediately available, official guidance permits the unused product to be immediately flushed down the toilet to mitigate the high risk of accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lumidol found in:

A-Z Index: